Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Insulet Corp (PODD)

Insulet Corp (PODD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Insulet Corp 100 NAGOG PARK ACTON MA 01720 USA

P: 978-600-7000

Description:

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.

Key Statistics

Overview:

Market Capitalization, $K 21,390,290
Enterprise Value, $K 21,872,590
Shares Outstanding, K 69,449
Annual Sales, $ 1,099 M
Annual Net Income, $ 16,800 K
Last Quarter Sales, $ 340,800 K
Last Quarter Net Income, $ -5,200 K
60-Month Beta 0.79
% of Insider Shareholders 0.90%
Float, K 68,824
% Float 99.10%
Short Volume Ratio 0.47

Growth:

1-Year Return 8.66%
3-Year Return 67.43%
5-Year Return 341.51%
5-Year Revenue Growth 199.41%
5-Year Earnings Growth 150.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.45 on 11/03/22
Next Earnings Date N/A
Earnings Per Share ttm 1.21
EPS Growth vs. Prev Qtr 850.00%
EPS Growth vs. Prev Year 125.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PODD Ratios

Ratio
Price/Earnings ttm 247.41
Price/Earnings forward 292.42
Price/Earnings to Growth N/A
Return-on-Equity % 18.19%
Return-on-Assets % 4.02%
Profit Margin % 1.53
Net Margin % -54.74
Debt/Equity 3.28
Price/Sales 18.92
Price/Cash Flow 278.26
Price/Book 48.58
Book Value/Share 6.16
Interest Coverage -1.33
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar